%0 Journal Article
%T Increasing survivors of anthracycline-related cardiomyopathy with breast cancer in trastuzumab era: thirty-one-year trends in a Japanese Community.
%A Watanabe M
%A Fujiki S
%A Okura Y
%A Toshikawa C
%A Ikarashi M
%A Kanbayashi C
%A Kaneko K
%A Kikuchi A
%A Sakata E
%A Tsuchida K
%A Ozaki K
%A Moro K
%A Kubota N
%A Kashimura T
%A Moriyama M
%A Sato N
%A Tanabe N
%A Koyama Y
%A Wakai T
%A Saijo Y
%A Inomata T
%J Breast Cancer
%V 0
%N 0
%D 2024 Aug 13
%M 39138789
%F 3.307
%R 10.1007/s12282-024-01623-0
%X <B>BACKGROUND: </B>Trastuzumab has improved breast cancer (BC) prognosis and reduced anthracycline use. However, the characteristic changes of anthracycline-related cardiomyopathy (ARCM) in patients with BC remain unclear. We aimed to update our understanding of ARCM in the trastuzumab era.<BR><B>METHODS: </B>This retrospective observational cohort study included 2959 patients with BC treated with anthracyclines at three regional cancer centers in Niigata City between 1990 and 2020. Seventy-five patients (2.5%) developed ARCM and were categorized into two groups: pre- 2007 (early phase) and post-2007 (late phase), corresponding to before and during the trastuzumab era in Japan.<BR><B>RESULTS: </B>ARCM incidence peaked at 6% in the 1990s, then decreased and stabilized at 2% until the 2010s. Survivors of anthracycline-treated BC increased more rapidly in the late phase, with four times as many patients with ARCM compared to the end of the early phase (26 and six, respectively). Although the rate of change in accumulation from the early phase to the late phase was slight in the anthracycline-treated BC group, it was more pronounced in the ARCM group (P < 0.001). Mean anthracycline use in the late phase was significantly lower than in the early phase (307 vs. 525 mg/m2, P < 0.001). Five-year survival rates in the late phase tended to be higher than early phase (45% and 28%, respectively. P = 0.058). Human epidermal growth factor receptor type 2 (HER2) positivity with trastuzumab therapy in the late phase was an independent predictor for mortality within 10 years (hazard ratio = 0.24, 95% confidence interval: 0.10-0.56; P = 0.001).<BR><B>CONCLUSIONS: </B>HER2-positive patients with ARCM receiving trastuzumab therapy had a better prognosis than HER2-positive and HER2-negative patients with ARCM not receiving trastuzumab therapy, and this trend has been increasing in the trastuzumab era. These findings highlight the importance of HER2-targeted treatments in improving prognosis for BC patients with ARCM.